Clinical Trial Update: Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD [Phase 3]

View source ↗

Summary

Tonix Pharmaceuticals' Phase 3 trial of the sublingual TNX-102 SL for military-related PTSD was terminated, with results posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• TNX-102 SL (cyclobenzaprine hydrochloride)

Snippet

Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: PTSD | Phase 3 | Status: TERMINATED | Results posted: 2024-05-22